Dendritic cells in cancer immunotherapy

Gall, Camille Le; Weiden, Jorieke; Eggermont, Loek J.; Figdor, Carl G.

doi:10.1038/s41563-018-0093-6

Cited by 106 publications

(60 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It includes donor lymphocyte infusion, 1 chimeric antigen receptor T cells, 2,3 natural killer cells, 4 virus-specific T cells, 5,6 and cancer vaccine using dendritic cells. 7 Peripheral blood mononuclear cell (MNC) collection by apheresis is the initial step for all these treatments. In this harvest procedure, a patient or donor's whole blood is separated into components of different density in a continuousflow centrifuge.…”

Section: Discussionmentioning

confidence: 99%

“…Adoptive cellular immunotherapy is one of the fastest‐growing fields in cancer therapy. It includes donor lymphocyte infusion, chimeric antigen receptor T cells, natural killer cells, virus‐specific T cells, and cancer vaccine using dendritic cells . Peripheral blood mononuclear cell (MNC) collection by apheresis is the initial step for all these treatments.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of peripheral blood mononuclear cell collection by leukapheresis

et al. 2019

View full text Add to dashboard Cite

BACKGROUND Adoptive immunotherapy using engineered lymphocytes has shown promising results in treating cancers even in patients who have failed other treatments. As the first essential step, the number of peripheral mononuclear cell (MNC) collection procedures is rapidly increasing. In this retrospective study, we reviewed the collection results to determine factors that affect MNC collection. STUDY DESIGN AND METHODS We reviewed 184 collections that were performed on 169 adult allogenic donors and patients with acute lymphoid leukemia, chronic lymphoid leukemia, lymphoma, multiple myeloma, or solid‐organ tumors. All the leukapheresis procedures were performed after a complete cell count with differential was obtained. Total blood volume (TBV) was defined as processed blood volume divided by patient blood volume. RESULTS There was a significant association between the precollection MNC count (pre‐MNC) and the MNC yields normalized by TBV (r = 0.926; p < 0.001) and a regression formula was created to predict MNC yields. Multiple regression analyses showed that pre‐MNC, TBV, and precollection hemoglobin were strongly associated with MNC yield (R 2 = 0.866; F (3180) = 388.472; p < 0.001), and pre‐MNC had the greatest influence on MNC yield (β = 0.960; p < 0.001) followed by TBV (β = 0.302; p < 0.001), and Hgb (β = 0.136; p < 0.001). CONCLUSION Our results suggest that the optimal time for MNC collection can be determined based on pre‐MNC and that processing volume should be determined based on collection goal and pre‐MNC to optimize and personalize the harvesting procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Evaluation of peripheral blood mononuclear cell collection by leukapheresis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Dendritic cells (DCs) are potent antigen-presenting cells and play a critical role in activating cellular and humoral immune responses [1][2][3][4][5][6][7][8][9]. Sipuleucel-T (Provenge), a cancer vaccine of autologous DCs, loaded with TAA, was approved by the United States Food and Drug Administration for the treatment of castration-resistant prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention

Chen

Liu

Jehng

et al. 2019

Cancers

View full text Add to dashboard Cite

Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in activating cellular and humoral immune responses. DC-based tumor vaccines targeting tumor-associated antigens (TAAs) have been extensively tested and demonstrated to be safe and potent in inducing anti-TAA immune responses in cancer patients. Sipuleucel-T (Provenge), a cancer vaccine of autologous DCs loaded with TAA, was approved by the United States Food and Drug Administration (FDA) for the treatment of castration-resistant prostate cancer. Sipuleucel-T prolongs patient survival, but has little or no effect on clinical disease progression or biomarker kinetics. Due to the overall limited clinical efficacy of tumor vaccines, there is a need to enhance their potency. PD-L1 is a key immune checkpoint molecule and is frequently overexpressed on tumor cells to evade antitumor immune destruction. Repeated administrations of PD-L1 or PD-1 antibodies have induced sustained tumor regression in a fraction of cancer patients. In this study, we tested whether vaccinations with DCs, loaded with a PD-L1 immunogen (PDL1-Vax), are able to induce anti-PD-L1 immune responses. We found that DCs loaded with PDL1-Vax induced anti-PD-L1 antibody and T cell responses in immunized mice and that PD-L1-specific CTLs had cytolytic activities against PD-L1+ tumor cells. We demonstrated that vaccination with PDL1-Vax DCs potently inhibited the growth of PD-L1+ tumor cells. In summary, this study demonstrates for the first time the principle and feasibility of DC vaccination (PDL1-Vax) to actively induce anti-PD-L1 antibody and T cell responses capable of inhibiting PD-L1+ tumor growth. This novel anti-PD-L1 vaccination strategy could be used for cancer treatment and prevention.

show abstract

“…Alternatively, engineering Fc region to increase affinity to DCs is also a critical aspect to improve the current design. In fact, DCs are able to induce long-lasting immunity against tumors by processing and presenting tumor cells and materials derived from the tumor [52].…”

Section: Bsabs: Lessons From Cancer Therapymentioning

confidence: 99%

Bispecific antibodies: Potential immunotherapies for HIV treatment

Fabozzi¹,

Pegu²,

Koup³

et al. 2019

Methods

View full text Add to dashboard Cite

Bispecific (bs) antibodies (Abs, bsAbs) are engineered immunoglobulins that contain two different antigen-binding sites in one molecule. bsAbs can be divided in two molecular formats; the IgGlike and non-IgG like. The structural elements of each format have implications for engaging the immune system. Elimination of HIV will need sophisticated approaches with immunotherapies being one of the strategies under investigation. Furthermore, HIV genetic variability and functional compromise of the adaptive CTL response complicate the potential usefulness of some immunotherapeutic strategies. Inclusion of novel HIV neutralizing Abs with high potency and breadth as components of bsAbs could represent alternative strategies for virus elimination by harnessing the adaptive immune response in vivo.

show abstract

Dendritic cells in cancer immunotherapy

Cited by 106 publications

References 10 publications

Evaluation of peripheral blood mononuclear cell collection by leukapheresis

Evaluation of peripheral blood mononuclear cell collection by leukapheresis

A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention

Bispecific antibodies: Potential immunotherapies for HIV treatment

Contact Info

Product

Resources

About